GlassScriptPhysician profile
Gigi A Geiger
NPI 1760658306
$10,305.59
in general payments reported to CMS, 2019-2025
31 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $109 · 2021: $1,447 · 2022: $1,210 · 2023: $982 · 2024: $5,613 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,759 · Travel and Lodging: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,759.49 |
| Travel and Lodging | $2,467.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,666.51 | 2020-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Watchman Flx |
| Medtronic, INC. | $2,532.97 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $1,196.76 | 2021-2024 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $659.87 | 2019-2025 | Relistor |
| Grt US Holding, INC. | $360.36 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $309.74 | 2019-2025 | Belbuca, Xtampza |
| Foundation Fusion Solutions, LLC | $295.73 | 2024 | |
| Abbvie INC. | $185.87 | 2024-2025 | |
| Spr Therapeutics, INC | $142.90 | 2025 | Sprint Pns System |
| Valinor Pharma, LLC | $140.20 | 2024-2025 | Movantik |
| Painteq LLC | $123.15 | 2023-2024 | Painteq |
| Nevro Corp. | $121.72 | 2019-2024 | Senza |
| Curonix LLC | $82.72 | 2022 | |
| Horizon Therapeutics Plc | $56.46 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $44.19 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $43.49 | 2025 | Qutenza |
| Indivior INC. | $37.54 | 2019 | |
| Kaleo, INC. | $35.57 | 2019 | |
| Bioventus LLC | $33.35 | 2024 | Durolane |
| Pernix Therapeutics Holdings, INC. | $28.80 | 2019 | |
| Amgen INC. | $27.55 | 2019 | |
| Daiichi Sankyo INC. | $25.62 | 2019 | |
| Vertos Medical, INC. | $24.82 | 2024 | Mild Device Kit |
| Trevena, INC. | $23.12 | 2023 | Olinvyk |
| Sanofi-Aventis U.S. LLC | $23.06 | 2023 | |
| Lilly USA, LLC | $17.32 | 2021 | |
| Assertio Therapeutics, INC. | $15.10 | 2019 | |
| Redhill Biopharma INC. | $14.24 | 2022 | |
| Hikma Pharmaceuticals USA | $13.17 | 2024 | Kloxxado |
| Depuy Synthes Sales INC. | $12.83 | 2019 | |
| Pfizer INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gigi Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.